Press releases
- Organon Announces HADLIMA™ (adalimumab-bwwd) Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National Formulary
- Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2023
- Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 15, 2024
- Organon’s XACIATO™ (clindamycin phosphate) Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis (BV) in Females Aged 12 and Older
- Organon affirms 2023 revenue and Adjusted EBITDA guidance and provides 2024 outlook
More ▼
Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | -- |
Average volume | -- |
---|---|
Shares outstanding | 255.64m |
Free float | 255.34m |
P/E (TTM) | 4.71 |
Market cap | 4.81bn USD |
EPS (TTM) | 3.99 USD |
Annual div (ADY) | 104.22 RUB |
---|---|
Annual div yield (ADY) | -- |
Div ex-date | Feb 22 2024 |
Div pay-date | Mar 14 2024 |
--
More ▼